| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer
|
Chiang, Chi-Lu
|
|
|
188 |
C |
p.
|
artikel
|
| 2 |
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer
|
Takam Kamga, Paul
|
|
|
188 |
C |
p.
|
artikel
|
| 3 |
Contents
|
|
|
|
188 |
C |
p.
|
artikel
|
| 4 |
Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426]
|
Sakata, Yoshihiko
|
|
|
188 |
C |
p.
|
artikel
|
| 5 |
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis
|
Wu, Haicheng
|
|
|
188 |
C |
p.
|
artikel
|
| 6 |
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
|
Peters, Solange
|
|
|
188 |
C |
p.
|
artikel
|
| 7 |
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)
|
Cheng, Ying
|
|
|
188 |
C |
p.
|
artikel
|
| 8 |
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
|
Zhao, Shen
|
|
|
188 |
C |
p.
|
artikel
|
| 9 |
Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis
|
Noritake, Osamu
|
|
|
188 |
C |
p.
|
artikel
|
| 10 |
Prognostic value of predominant subtype in pathological stage II–III lung adenocarcinoma with epidermal growth factor receptor mutation
|
Kitagawa, Shingo
|
|
|
188 |
C |
p.
|
artikel
|
| 11 |
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma
|
Burns, Laura
|
|
|
188 |
C |
p.
|
artikel
|
| 12 |
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions
|
Liu, Stephen V.
|
|
|
188 |
C |
p.
|
artikel
|
| 13 |
SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters
|
Zhang, Yao-Hua
|
|
|
188 |
C |
p.
|
artikel
|
| 14 |
The Effect of Social Vulnerability on Initial Stage and Treatment for Non-Small Cell Lung Cancer
|
Stuart, Christina M.
|
|
|
188 |
C |
p.
|
artikel
|
| 15 |
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
|
Cho, Byoung Chul
|
|
|
188 |
C |
p.
|
artikel
|
Tijdschrift beschrijving